CA2781408A1 - Biomarkers of cancer - Google Patents

Biomarkers of cancer Download PDF

Info

Publication number
CA2781408A1
CA2781408A1 CA2781408A CA2781408A CA2781408A1 CA 2781408 A1 CA2781408 A1 CA 2781408A1 CA 2781408 A CA2781408 A CA 2781408A CA 2781408 A CA2781408 A CA 2781408A CA 2781408 A1 CA2781408 A1 CA 2781408A1
Authority
CA
Canada
Prior art keywords
cancer
tumor
stage
antigens
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2781408A
Other languages
English (en)
French (fr)
Inventor
Douglas D. Taylor
Cicek Gercel-Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Louisville Research Foundation ULRF
Original Assignee
University of Louisville Research Foundation ULRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Louisville Research Foundation ULRF filed Critical University of Louisville Research Foundation ULRF
Publication of CA2781408A1 publication Critical patent/CA2781408A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2781408A 2009-11-20 2010-11-19 Biomarkers of cancer Abandoned CA2781408A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26323509P 2009-11-20 2009-11-20
US61/263,235 2009-11-20
PCT/US2010/057427 WO2011063232A1 (en) 2009-11-20 2010-11-19 Biomarkers of cancer

Publications (1)

Publication Number Publication Date
CA2781408A1 true CA2781408A1 (en) 2011-05-26

Family

ID=44060024

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2781408A Abandoned CA2781408A1 (en) 2009-11-20 2010-11-19 Biomarkers of cancer

Country Status (6)

Country Link
US (1) US20150005187A1 (https=)
EP (1) EP2501845A4 (https=)
JP (1) JP2013511728A (https=)
AU (1) AU2010321787B2 (https=)
CA (1) CA2781408A1 (https=)
WO (1) WO2011063232A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102393458A (zh) * 2011-08-24 2012-03-28 绍兴市人民医院 一种早期乳腺癌血清诊断试剂及其检测方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186293A1 (en) * 2012-12-31 2014-07-03 University Of Louisville Research Foundation, Inc. Immunoglobulin-bound extracellular vesicles and uses thereof
JP2016507748A (ja) * 2013-01-31 2016-03-10 アリゾナ ボード オブ リージェンツ， ア ボディー コーポレイト オブ ザ ステート オブ アリゾナ， アクティング フォー アンド オン ビハーフ オブ アリゾナ ステート ユニバーシティー 卵巣癌の早期発見のための自己抗体サイン
WO2016164815A1 (en) * 2015-04-10 2016-10-13 Applied Proteomics, Inc. Protein biomarker panels for detecting colorectal cancer and advanced adenoma
CN116670510A (zh) * 2020-10-05 2023-08-29 福瑞诺姆控股公司 用于结肠细胞增殖性病症的早期检测的标志物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2780161B1 (fr) 1998-06-17 2000-09-29 Centre Nat Rech Scient Procede de diagnostic precoce du cancer base sur la recherche d'auto-anticorps diriges contre la proteine csk et trousse pour sa mise en oeuvre
US20030190602A1 (en) * 2001-03-12 2003-10-09 Monogen, Inc. Cell-based detection and differentiation of disease states
US20030119079A1 (en) 2001-09-19 2003-06-26 The Regents Of The University Of Michigan Detection and treatment of cancers of the breast
WO2003026494A2 (en) * 2001-09-28 2003-04-03 Sidney Kimmel Cancer Center Galectins-1-and-4 in tumor development
US20050158737A1 (en) * 2002-03-27 2005-07-21 Alison Banham Tumour associated antigens
GB0412301D0 (en) * 2004-06-02 2004-07-07 Diagenic As Product and method
JP2007322211A (ja) * 2006-05-31 2007-12-13 Green Peptide Co Ltd がん患者の予後予測方法
ATE535805T1 (de) 2007-01-26 2011-12-15 Univ Louisville Res Found Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen
WO2009145815A2 (en) * 2008-04-01 2009-12-03 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102393458A (zh) * 2011-08-24 2012-03-28 绍兴市人民医院 一种早期乳腺癌血清诊断试剂及其检测方法
CN102393458B (zh) * 2011-08-24 2013-12-18 绍兴市人民医院 一种早期乳腺癌血清诊断试剂

Also Published As

Publication number Publication date
EP2501845A1 (en) 2012-09-26
EP2501845A4 (en) 2013-04-24
AU2010321787A1 (en) 2012-06-14
WO2011063232A1 (en) 2011-05-26
JP2013511728A (ja) 2013-04-04
US20150005187A1 (en) 2015-01-01
AU2010321787B2 (en) 2015-06-11

Similar Documents

Publication Publication Date Title
Caron et al. Cancer immunomics using autoantibody signatures for biomarker discovery
US7112408B2 (en) Detection of ovarian cancer based upon alpha-haptoglobin levels
Yang et al. Identification of candidate biomarkers for the early detection of nasopharyngeal carcinoma by quantitative proteomic analysis
US20150005187A1 (en) Biomarkers of Cancer
EP1775590A1 (en) Non-invasive in vitro method to detect transitional cell carcinoma of the bladder
US20100279419A1 (en) Detection of saliva proteins modulated secondary to ductal carcinoma in situ of the breast
AU2023210591B2 (en) Markers of endometrial cancer
Mueller et al. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients
Periyasamy et al. Identification and validation of differential plasma proteins levels in epithelial ovarian cancer
Giri et al. Targeted proteomics using parallel reaction monitoring confirms salivary proteins indicative of metastatic triple-negative breast cancer
US20120277326A1 (en) Biomarkers of cancer
Streckfus et al. A comparison of the proteomic expression in pooled saliva specimens from individuals diagnosed with ductal carcinoma of the breast with and without lymph node involvement
Taylor et al. Characterization of humoral responses of ovarian cancer patients: Antibody subclasses and antigenic components
Ruibal et al. Cytosolic levels of neuron-specific enolase in squamous cell carcinomas of the lung
EP2115473B1 (en) Markers for transformed epithelium and potential targets for therapy of cancer of the gingivo buccal complex
WO2013166343A2 (en) Mrm-ms signature assay
KR101795595B1 (ko) 비소세포성 폐암의 혈액학적 진단 방법
Juanes-Velasco et al. Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid. Cancers 2022, 14, 449
US20060046276A1 (en) Acetyl-LDL receptor as a biomarker for breast cancer
Baldetorp et al. Analysis of protein expression in pure cell nuclei populations isolated from human breast cancer tissue by DNA flow cytometric sorting
CN121410263A (zh) 胆道癌免疫治疗相关的尿液蛋白标志物及其应用
GB2541712A (en) Autoantibody biomarkers for gastric cancer

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20161121